533 related articles for article (PubMed ID: 15603252)
1. LNA-antisense rivals siRNA for gene silencing.
Jepsen JS; Wengel J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
[TBL] [Abstract][Full Text] [Related]
2. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
3. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
Orum H; Wengel J
Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
[TBL] [Abstract][Full Text] [Related]
4. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
[TBL] [Abstract][Full Text] [Related]
5. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications.
Veedu RN; Wengel J
Chem Biodivers; 2010 Mar; 7(3):536-42. PubMed ID: 20232325
[TBL] [Abstract][Full Text] [Related]
6. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
Jepsen JS; Sørensen MD; Wengel J
Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076
[TBL] [Abstract][Full Text] [Related]
7. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.
Elmén J; Thonberg H; Ljungberg K; Frieden M; Westergaard M; Xu Y; Wahren B; Liang Z; Ørum H; Koch T; Wahlestedt C
Nucleic Acids Res; 2005; 33(1):439-47. PubMed ID: 15653644
[TBL] [Abstract][Full Text] [Related]
8. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.
Vester B; Wengel J
Biochemistry; 2004 Oct; 43(42):13233-41. PubMed ID: 15491130
[TBL] [Abstract][Full Text] [Related]
9. Free-radical ring closure to conformationally locked α-L-carba-LNAs and synthesis of their oligos: nuclease stability, target RNA specificity, and elicitation of RNase H.
Li Q; Yuan F; Zhou C; Plashkevych O; Chattopadhyaya J
J Org Chem; 2010 Sep; 75(18):6122-40. PubMed ID: 20738147
[TBL] [Abstract][Full Text] [Related]
10. Oral delivery of siRNA and antisense oligonucleotides.
Akhtar S
J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
[TBL] [Abstract][Full Text] [Related]
11. Determination of affinity constants of locked nucleic acid (LNA) and DNA duplex formation using label free sensor technology.
Möhrle BP; Kumpf M; Gauglitz G
Analyst; 2005 Dec; 130(12):1634-8. PubMed ID: 16284662
[TBL] [Abstract][Full Text] [Related]
12. siRNA-mediated antitumorigenesis for drug target validation and therapeutics.
Lu PY; Xie FY; Woodle MC
Curr Opin Mol Ther; 2003 Jun; 5(3):225-34. PubMed ID: 12870431
[TBL] [Abstract][Full Text] [Related]
13. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
[TBL] [Abstract][Full Text] [Related]
14. Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.
Kasuya T; Hori S; Watanabe A; Nakajima M; Gahara Y; Rokushima M; Yanagimoto T; Kugimiya A
Sci Rep; 2016 Jul; 6():30377. PubMed ID: 27461380
[TBL] [Abstract][Full Text] [Related]
15. Zorro locked nucleic acid induces sequence-specific gene silencing.
Ge R; Heinonen JE; Svahn MG; Mohamed AJ; Lundin KE; Smith CI
FASEB J; 2007 Jun; 21(8):1902-14. PubMed ID: 17314142
[TBL] [Abstract][Full Text] [Related]
16. Syntheses and base-pairing properties of locked nucleic acid nucleotides containing hypoxanthine, 2,6-diaminopurine, and 2-aminopurine nucleobases.
Koshkin AA
J Org Chem; 2004 May; 69(11):3711-8. PubMed ID: 15153000
[TBL] [Abstract][Full Text] [Related]
17. The application of locked nucleic acids in the treatment of cancer.
Frieden M; Orum H
IDrugs; 2006 Oct; 9(10):706-11. PubMed ID: 17016778
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
[TBL] [Abstract][Full Text] [Related]
19. NMR studies of fully modified locked nucleic acid (LNA) hybrids: solution structure of an LNA:RNA hybrid and characterization of an LNA:DNA hybrid.
Nielsen KE; Rasmussen J; Kumar R; Wengel J; Jacobsen JP; Petersen M
Bioconjug Chem; 2004; 15(3):449-57. PubMed ID: 15149171
[TBL] [Abstract][Full Text] [Related]
20. An LNA-based loss-of-function assay for micro-RNAs.
Naguibneva I; Ameyar-Zazoua M; Nonne N; Polesskaya A; Ait-Si-Ali S; Groisman R; Souidi M; Pritchard LL; Harel-Bellan A
Biomed Pharmacother; 2006 Nov; 60(9):633-8. PubMed ID: 16962735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
